Indication
Anthrax vaccination
Anthrax vaccination is an immunization indicated for active protection against infection caused by the spore-forming bacterium *Bacillus anthracis*. Read more about Anthrax vaccination
1 drugs 1 manufacturers
Drugs that treat it
Common Anthrax vaccination therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAnthrax vaccination is an immunization indicated for active protection against infection caused by the spore-forming bacterium *Bacillus anthracis*.
It is utilized both for pre-exposure prophylaxis in populations at elevated risk of exposure—such as specific military personnel, laboratory researchers, and handlers of potentially infected animals—and for post-exposure prophylaxis following suspected or confirmed spore exposure.
Infection typically manifests in cutaneous, gastrointestinal, or inhalational forms, with the respiratory tract, skin, and regional lymphatic systems primarily affected.
Pathophysiologically, the disease is driven by bacterial spore germination and the subsequent release of binary exotoxins—edema toxin and lethal toxin—which induce severe localized necrosis, extensive edema, systemic toxemia, bacteremia, and high fatality rates if unchecked.
- fda.gov
Anthrax vaccination is an immunization indicated for active protection against infection caused by the spore-forming bacterium *Bacillus anthracis* It is utilized both for pre-exposure prophylaxis in populations at elevated risk of exposure—such as specific military personnel, laboratory researchers, and handlers of potentially infected animals—and for post-exposure prophylaxis following suspected or confirmed spore exposure
- fda.gov
Anthrax vaccination is an immunization indicated for active protection against infection caused by the spore-forming bacterium *Bacillus anthracis*
- cdc.gov
It is utilized both for pre-exposure prophylaxis in populations at elevated risk of exposure—such as specific military personnel, laboratory researchers, and handlers of potentially infected animals—and for post-exposure prophylaxis following suspected or confirmed spore exposure
- fda.gov
Infection typically manifests in cutaneous, gastrointestinal, or inhalational forms, with the respiratory tract, skin, and regional lymphatic systems primarily affected Pathophysiologically, the disease is driven by bacterial spore germination and the subsequent release of binary exotoxins—edema toxin and lethal toxin—which induce severe localized necrosis, extensive edema, systemic toxemia, bacteremia, and high fatality rates if unchecked
- cdc.gov
Infection typically manifests in cutaneous, gastrointestinal, or inhalational forms, with the respiratory tract, skin, and regional lymphatic systems primarily affected Pathophysiologically, the disease is driven by bacterial spore germination and the subsequent release of binary exotoxins—edema toxin and lethal toxin—which induce severe localized necrosis, extensive edema, systemic toxemia, bacteremia, and high fatality rates if unchecked
Personalize your experience
Follow Anthrax vaccination and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.